<PAGE>
---------------------------
OMB APPROVAL
---------------------------
OMB number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response... 14.90
---------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
Neurocrine Biosciences, Inc.
-------------------------------------------------------------
(Name of Issuer)
Common Stock, no par value
---------------------------------------------------
(Title of Class of Securities)
64125C10
-----------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 Pages
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64125C10 13G PAGE 2 OF 5 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Abingworth Bioventures SICAV
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
Luxembourg
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 778,970
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
- 0 -
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 778,970
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
- 0 -
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
778,970
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
4.6%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 3 pages
<PAGE>
Item 1(a). Name of Issuer: Neurocrine Biosciences, Inc.
- ---------- ---------------
Item 1(b). Address of Issuer's Principal Executive Offices:
- ---------- ------------------------------------------------
3050 Science Park Road, San Diego, CA 92121
Item 2(a). Name of Person Filing: Abingworth Bioventures SICAV ("ABS")
- ---------- ----------------------
Item 2(b). Address of Principal Business Office or, if None, Residence:
- ---------- -----------------------------------------------------------
The address of the principal business office of ABS is 231 Val
des Bons Malades, L-2121 Luxembourg-Kirchberg.
Item 2(c). Citizenship: ABS is a corporation organized under the laws of
- ---------- ------------
Luxembourg.
Item 2(d). Title of Class of Securities: Common Stock, no par value.
- ---------- -----------------------------
Item 2(e). CUSIP Number: 64125C10
- ---------- ------------
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
- ------- ----------------------------------------------------------
13d-2(b), check whether the person filing is a:
-----------------------------------------------
(a) [ ] Broker or Dealer registered under Section 15 of the
Securities Exchange Act of 1934 (the "Act").
(b) [ ] Bank as defined in Section 3(a)(6) of the Act.
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the
Act.
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940.
(e) [ ] Investment Adviser registered under Section 203 of
the Investment Advisers Act of 1940.
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income Security
Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
of the Act.
(g) [ ] Parent Holding Company, in accordance with Rule 13d-
1(b)(ii)(G) of the Act.
(h) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(H) of the
Act.
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b) or Rule13d-2(b).
Page 3 of 5 pages
<PAGE>
Item 4. Ownership.
- ------- ----------
(a) Amount Beneficially Owned: ABS is the record and
beneficial owner of 778,970 shares of Common Stock as of
December 31, 1997.
(b) Percent of Class: 4.6%. The foregoing percentage is
calculated based on the 17,041,235 shares of Common
Stock reported to be outstanding in the Quarterly
Report on Form 10-Q of Neurocrine Biosciences, Inc.
for the quarter ended September 30, 1997.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
778,970 shares.
(ii) shared power to vote or to direct the vote:
0 shares.
(iii) sole power to dispose or to direct the disposition of:
778,970 shares.
(iv) shared power to dispose or to direct the disposition of:
0 shares.
Item 5. Ownership of Five Percent or Less of a Class.
- ------- ---------------------------------------------
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check
the following: [X].
Item 6. Ownership of More than Five Percent on Behalf of Another
- ------- --------------------------------------------------------
Person.
-------
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
- ------- ----------------------------------------------------------
Acquired the Security Being Reported on by the Parent Holding
--------------------------------------------------------------
Company.
-------
Not applicable.
Item 8. Identification and Classification of Members of the Group.
- ------- ----------------------------------------------------------
Not applicable
Item 9. Notice of Dissolution of Group.
- ------- -------------------------------
Not applicable.
Item 10 Certification.
- ------- --------------
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b).
Page 4 of 5 pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, the
undersigned certifies that the information set forth in this statement is true,
complete and correct.
Date: February 13, 1998
ABINGWORTH BIOVENTURES SICAV
By: /s/Karl U. SANNE
----------------
Name: Karl U. SANNE
Title: Director
--------
By: /s/Fernand HEIM
---------------
Name: Fernand HEIM
Title: Mandatory
---------
Page 5 of 5 pages
